trending Market Intelligence /marketintelligence/en/news-insights/trending/U8X4vGUoYo1uOziV6DuZ4Q2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Seres Therapeutics ulcerative colitis drug nabs US FDA orphan drug designation

Blog

JMP Securities is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

M&A rebound sparks optimism for near-term deal activity

Blog

Needham & Company is Now Available in the S&P Global Market Intelligence Aftermarket Research Collection

Blog

Banking Essentials Newsletter - February Edition


Seres Therapeutics ulcerative colitis drug nabs US FDA orphan drug designation

Seres Therapeutics Inc. said the U.S. Food and Drug Administration granted orphan drug designation to its SER-287 microbiome therapeutic candidate for treating pediatric patients with ulcerative colitis.

The designation follows a review of data from the phase 1b study evaluating SER-287 for ulcerative colitis treatment. The company expects results from the trial in early 2018.

Ulcerative colitis is a serious chronic condition affecting about 700,000 people in the U.S. The disease results in inflammation of the colon and rectum and may lead to colon removal.